Takeda Announces Program Updates During COVID-19

Industry News
The following is information shared with the bleeding disorders community by Takeda.

“Takeda has been closely monitoring the news surrounding COVID-19. Our highest priority is the health and safety of our community during this uncertain time.
We are taking steps to help ensure the community’s safety including postponing upcoming educational events such as our HELLO TALK® programs. We appreciate your understanding and we will be regularly updating our events on our website.
A global pandemic such as COVID-19 can cause alarm but we urge you to consult with your healthcare provider to discuss questions regarding your condition and COVID-19. In addition, the CDC (Centers for Disease Control and Prevention) website includes information on things like COVID-19 symptoms, how to protect yourself and others from the virus, and who may be at higher risk for complications due to the virus. The National Hemophilia Foundation and the Hemophilia Federation of America are also helpful resources for bleeding disorders patients and caregivers.
For those of you who are currently on Takeda treatments, based on current assessments of our supply chain, we do not anticipate any potential supply disruption in the near-term due to the COVID-19 outbreak. Please know that we will continue to monitor the situation as it evolves and take all necessary actions in an effort to ensure supply continuity for the people we serve. If you have been prescribed a Takeda therapy and have questions, you can call our Hematology Support Center at (888) 229-8379 Monday through Friday from 8:30 a.m. to 8:00 p.m.
We are in this together with you.”